Palliative chemotherapy (2nd line) with imatinib (Glivec) in patients with bile duct cancer

Trial Profile

Palliative chemotherapy (2nd line) with imatinib (Glivec) in patients with bile duct cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Imatinib (Primary)
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Acronyms GlivecGG
  • Most Recent Events

    • 02 Sep 2009 Status changed from not stated to discontinued as reported by ISRCTN: Current Controlled Trials.
    • 10 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top